Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial GlobeNewswire - Mon Oct 14, 7:37AM CDT CMTX - Mon Oct 14, 7:37AM CDT
-- Biopsy tissue expresses the complement C5a receptor 1 and the leukotriene LTB4 receptor BLT1 on and within the surface of the eye, a previously unreported finding
Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress GlobeNewswire - Thu Oct 10, 7:45AM CDT CMTX - Thu Oct 10, 7:45AM CDT
-- Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patients
Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference GlobeNewswire - Wed Sep 18, 7:02AM CDT CMTX - Wed Sep 18, 7:02AM CDT
Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene...
Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease Zacks Equity Research - Zacks Investment Research - Mon Sep 16, 9:29AM CDT Zacks Equity Research - ZACKS - Mon Sep 16, 9:29AM CDT
The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.
Akari Therapeutics' Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid GlobeNewswire - Fri Sep 13, 7:00AM CDT CMTX - Fri Sep 13, 7:00AM CDT
Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene...
Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More Ekta Bagri - Zacks Investment Research - Wed Sep 4, 9:02AM CDT Ekta Bagri - ZACKS - Wed Sep 4, 9:02AM CDT
Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.
Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September GlobeNewswire - Tue Sep 3, 6:00AM CDT CMTX - Tue Sep 3, 6:00AM CDT
Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene...
Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease Zacks Equity Research - Zacks Investment Research - Mon Sep 2, 8:17AM CDT Zacks Equity Research - ZACKS - Mon Sep 2, 8:17AM CDT
The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.
Thinking about buying stock in Aurora Cannabis, Akari Therapeutics, Big Lots, Campbell Soup, or Walt Disney Co? PR Newswire - Fri Aug 30, 8:34AM CDT CMTX - Fri Aug 30, 8:34AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, BIG, CPB, and DIS.
Akari Therapeutics' Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA) GlobeNewswire - Fri Aug 30, 6:00AM CDT CMTX - Fri Aug 30, 6:00AM CDT
Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene...
Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress GlobeNewswire - Thu Aug 29, 7:06AM CDT CMTX - Thu Aug 29, 7:06AM CDT
- Positive early safety and efficacy data with nomacopan
Thinking about buying stock in Aurora Cannabis, Akari Therapeutics, Walt Disney Co, Presidio, or Tilray? PR Newswire - Wed Aug 14, 8:31AM CDT CMTX - Wed Aug 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, DIS, PSDO, and TLRY.
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) GlobeNewswire - Wed Aug 14, 7:01AM CDT CMTX - Wed Aug 14, 7:01AM CDT
-- Fast Track designation by the U.S. Food and Drug Administration (FDA) facilitates the development and expedites the review of new medicines like nomacopan that treat serious unmet medical needs and...
Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopan's bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease GlobeNewswire - Fri Aug 9, 7:30AM CDT CMTX - Fri Aug 9, 7:30AM CDT
-- New data from bullous pemphigoid (BP) patients and pemphigoid disease (PD) models generated by Dr. Christian Sadik's group at University of Lubeck, Germany published in the August 2019 edition of JCI...
Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, 2019 GlobeNewswire - Wed Jul 31, 8:57AM CDT CMTX - Wed Jul 31, 8:57AM CDT
Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems...
Alexion's Ultomiris Receives EU Approval for PNH in Adults Zacks Equity Research - Zacks Investment Research - Thu Jul 4, 7:35AM CDT Zacks Equity Research - ZACKS - Thu Jul 4, 7:35AM CDT
Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults.
Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering GlobeNewswire - Fri Jun 28, 8:23AM CDT CMTX - Fri Jun 28, 8:23AM CDT
Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems...
Alexion Receives FDA Approval for Label Expansion of Soliris Zacks Equity Research - Zacks Investment Research - Fri Jun 28, 7:45AM CDT Zacks Equity Research - ZACKS - Fri Jun 28, 7:45AM CDT
Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder.
Alexion's sBLA for Ultomiris Gets Priority Review From FDA Zacks Equity Research - Zacks Investment Research - Fri Jun 21, 10:05AM CDT Zacks Equity Research - ZACKS - Fri Jun 21, 10:05AM CDT
The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.
Akari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical Progress GlobeNewswire - Wed May 29, 6:45AM CDT CMTX - Wed May 29, 6:45AM CDT
-- Further clinical data from BP and AKC trials anticipated in 2019
